Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6659b9f88f4eb2c7adc8137591282bc |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
filingDate |
2018-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87692b122e2445b982ffa2213832d9ef http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_acab65d924272b9829dd81093b904e4c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_303d51cd0482f66d3fd832ec97980fae http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95d9e12b91853b61565d6405cac3c4dc |
publicationDate |
2019-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2019052165-A |
titleOfInvention |
Monoclonal antibody against fibroblast growth factor receptor 2 |
abstract |
The present invention provides a pharmaceutical composition for use in the treatment of solid cancer including gastric cancer that overexpresses fibroblast growth factor receptor 2 (FGFR2IIIb). A pharmaceutical composition comprising a humanized or human monoclonal antibody comprising a light chain variable region and a heavy chain variable region having a specific sequence that binds to FGFR2IIIb, and a physiologically acceptable carrier. [Selection] Figure 9 |
priorityDate |
2008-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |